News | August 08, 2024
JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
Expect the international business including CDMO business to pick-up in the second half of the financial year
Expect the international business including CDMO business to pick-up in the second half of the financial year
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Records the largest number of videos of people saying the same sentence uploaded to Facebook in one hour to raise awareness on Iron Deficiency Anaemia
Subscribe To Our Newsletter & Stay Updated
